Literature DB >> 32959935

PRESENTATION OF PAEDIATRIC TYPE 1 DIABETES IN MELBOURNE, AUSTRALIA DURING THE INITIAL STAGES OF THE COVID-19 PANDEMIC.

Gabby Atlas1,2, Farrah Rodrigues3,4, Yvette Moshage5,6, John Welch3, Mary White1,7,8, Michele A O'Connell1,6.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32959935      PMCID: PMC7537060          DOI: 10.1111/jpc.15081

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


× No keyword cloud information.
Dear Editor,

PRESENTATION OF PAEDIATRIC TYPE 1 DIABETES IN MELBOURNE, AUSTRALIA DURING THE INITIAL STAGES OF THE COVID‐19 PANDEMIC

Since the commencement of social isolation in the COVID‐19 pandemic (first case, 25 January; restrictions commenced, 13 March), paediatric diabetes centres across Australia have voiced concerns about an apparent reduction in new presentations of type 1 diabetes mellitus (T1DM). Reports from Italy and the USA have described delayed hospital presentations with severe diabetic ketoacidosis (DKA) at first presentation with T1DM during the COVID‐19 pandemic. , To date, there are no published Australian data on the impact of COVID‐19 on childhood T1DM presentations. Combined, the Royal Children's Hospital Melbourne and Monash Children's Hospital oversee the management of the majority of paediatric T1DM in Victoria (~80%). An audit of new presentations of T1DM (both total numbers and proportion presenting in DKA) was conducted across both sites from February to May for the years 2017–2020 inclusive. The severity of DKA at presentation (mild = pH 7.2–7.35, bicarbonate >10; moderate = pH 7.1–7.2, bicarbonate 5–10; severe = pH <7.1, bicarbonate <5) and admissions to the intensive care unit (ICU) were recorded. The absolute number of new presentations of T1DM between February and May in 2020 was similar to previous years, although 2019 represented an unexplained relative increase in numbers (Table 1). DKA severity and ICU admissions were similar for all years. Based on a combined estimation from 2017 to 2019, there was no difference between the expected rate of DKA (42.5 vs. 51.7%, P = 0.2) or severe DKA (37.2 vs. 43.3%, P = 0.5) in 2020. No individual was diagnosed with COVID‐19.
Table 1

Paediatric T1DM presentations to Royal Children's Hospital and Monash Children's Hospital February–May 2017–2020

2017201820192020p
Number diagnosed (February–May), n 58578958
Male, n (%) 39 (67.2)29 (50.9)50 (56.2)32 (55.2)0.3
ICU admission, n (%) 8 (13.8)8 (14.6)9 (10.1)15 (25.9)0.07
DKA, n (%) 20 (34.5)25 (43.9)41 (46.1)30 (51.7)0.3
Mild 6 (30)10 (40)19 (46.3)6 (20)0.1
Moderate 4 (20)6 (24)9 (21.9)11 (36.7)0.5
Severe 10 (50)9 (36)13 (31.7)13 (43.3)0.5

Between year proportions were analysed using a χ2 test.

ICU, intensive care unit; DKA, diabetic ketoacidosis.

Paediatric T1DM presentations to Royal Children's Hospital and Monash Children's Hospital February–May 2017–2020 Between year proportions were analysed using a χ2 test. ICU, intensive care unit; DKA, diabetic ketoacidosis. The overall incidence of paediatric T1DM is increasing, but total numbers and severity of presentations fluctuate over time. Concerns regarding increased severity at presentation with paediatric T1DM (due a perceived reduction in access to health‐care services and broader community fear in the setting of the pandemic) have not been borne out in this data. While no statistical difference in the proportion of new presentations requiring ICU admission was seen in 2020, the twofold increase in ICU admissions may reflect the unexpected increase in bed capacity (possibly due to decreased surgical procedures and a reduction in ED presentations). The successful avoidance of the projected pandemic‐related health‐care crisis in Australia in the period reported herein may explain the difference compared to reports from more severely impacted regions. The potential impact of the COVID‐19 pandemic and subsequent societal changes on paediatric T1DM presentations in Australasia is not yet known and ongoing collaborative data collection at a national or Australasian level is required.
  4 in total

Review 1.  Global burden of the COVID-19 associated patient-related delay in emergency healthcare: a panel of systematic review and meta-analyses.

Authors:  Vahid Mogharab; Mahshid Ostovar; Jakub Ruszkowski; Syed Zohaib Maroof Hussain; Rajeev Shrestha; Uzair Yaqoob; Poorya Aryanpoor; Amir Mohammad Nikkhoo; Parasta Heidari; Athar Rasekh Jahromi; Esmaeil Rayatdoost; Anwar Ali; Farshid Javdani; Roohie Farzaneh; Aref Ghanaatpisheh; Seyed Reza Habibzadeh; Mahdi Foroughian; Sayyed Reza Ahmadi; Reza Akhavan; Bita Abbasi; Behzad Shahi; Arman Hakemi; Ehsan Bolvardi; Farhad Bagherian; Mahsa Motamed; Sina Taherzadeh Boroujeni; Sheida Jamalnia; Amir Mangouri; Maryam Paydar; Neda Mehrasa; Dorna Shirali; Francesco Sanmarchi; Ayesha Saeed; Narges Azari Jafari; Ali Babou; Navid Kalani; Naser Hatami
Journal:  Global Health       Date:  2022-06-08       Impact factor: 10.401

2.  Comparison of Initial Presentation of Pediatric Diabetes Before and During the Coronavirus Disease 2019 Pandemic Era.

Authors:  Yoonha Lee; Minseung Kim; Kyeongeun Oh; Eungu Kang; Young-Jun Rhie; Jieun Lee; Yong Hee Hong; Young-Lim Shin; Jae Hyun Kim
Journal:  J Korean Med Sci       Date:  2022-06-06       Impact factor: 5.354

3.  The association between COVID-19 and type 1 diabetes mellitus: A systematic review.

Authors:  Mahmoud Nassar; Nso Nso; Bahaaeldin Baraka; Mostafa Alfishawy; Mahmoud Mohamed; Akwe Nyabera; Issac Sachmechi
Journal:  Diabetes Metab Syndr       Date:  2021-02-10

Review 4.  The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis.

Authors:  Masoud Rahmati; Maryam Keshvari; Shahrzad Mirnasuri; Dong K Yon; Seung W Lee; Jae Il Shin; Lee Smith
Journal:  J Med Virol       Date:  2022-07-22       Impact factor: 20.693

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.